Literature DB >> 26635032

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.

Thomas Dejoie1, Michel Attal2, Philippe Moreau1, Jean-Luc Harousseau3, Herve Avet-Loiseau4.   

Abstract

Response criteria for multiple myeloma are based upon changes in monoclonal protein levels quantified using serum and/or urine protein electrophoresis. The latter lacks sensitivity at low monoclonal protein levels and since 2001, the serum free light chain test has been available and its clinical utility proven, yet guidelines have not recommended it as a replacement for urine assessment. Herein we evaluated responses using serum free light chain measurements and serum and urine electrophoresis after 2 and 4 cycles of therapy and after stem cell transplantation in 25 light chain and 157 intact immunoglobulin myeloma patients enrolled in the IFM 2007-02 MM trial. All 25 light chain patients had measurable disease by serum free light chain and urine methods at presentation. By contrast 98 out of 157 intact immunoglobulin patients had measurable disease by serum free light chain compared to 55 out of 157 by urine electrophoresis. In all patients there was substantial agreement between predicate (serum/urine protein electrophoresis) and test (serum protein electrophoresis and serum free light chain) methods for response assessment (Weighted Kappa=0.83). Urine immunofixation became negative in 47% light chain and 43% intact immunoglobulin patients after 2 cycles of therapy. At this time the serum free light chain ratio normalised in only 11% and 27% patients, respectively. In summary we found good agreement between methods for response assessment, but the serum free light chain test provided greater sensitivity than urine electrophoresis for monitoring. To our knowledge this is the first report comparing both methods for response assignment based on the International Myeloma Working Group guidelines. (Clinical Trials Register.eu identifier: 2007-005204-40). Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26635032      PMCID: PMC4815727          DOI: 10.3324/haematol.2015.126797

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  41 in total

1.  Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Martha Q Lacy; Jerry A Katzmann; S Vincent Rajkumar; Roshini S Abraham; Suzanne R Hayman; Shaji K Kumar; Raynell Clark; Robert A Kyle; Mark R Litzow; David J Inwards; Stephen M Ansell; Ivana M Micallef; Luis F Porrata; Michelle A Elliott; Patrick B Johnston; Philip R Greipp; Thomas E Witzig; Steven R Zeldenrust; Stephen J Russell; Dennis Gastineau; Morie A Gertz
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

2.  Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains.

Authors:  Mark A Dawson; Sushrut Patil; Andrew Spencer
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

3.  Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.

Authors:  Mohammad R Nowrousian; Dieter Brandhorst; Christiane Sammet; Michaela Kellert; Rainer Daniels; Philipp Schuett; Miriam Poser; Siemke Mueller; Peter Ebeling; Anja Welt; Arthur R Bradwell; Ulrike Buttkereit; Bertram Opalka; Michael Flasshove; Thomas Moritz; Siegfried Seeber
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

Review 4.  Free light chains of immunoglobulins: clinical laboratory analysis.

Authors:  S S Levinson; D F Keren
Journal:  Clin Chem       Date:  1994-10       Impact factor: 8.327

5.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

6.  Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies.

Authors:  Peter G Hill; Julia M Forsyth; Baldeep Rai; Stewart Mayne
Journal:  Clin Chem       Date:  2006-07-20       Impact factor: 8.327

7.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

8.  Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.

Authors:  Jerry A Katzmann; Angela Dispenzieri; Robert A Kyle; Melissa R Snyder; Matthew F Plevak; Dirk R Larson; Roshini S Abraham; John A Lust; L Joseph Melton; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2006-12       Impact factor: 7.616

9.  Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?

Authors:  Robert Beetham; Julie Wassell; Michael J Wallage; Alastair J Whiteway; Jacky A James
Journal:  Ann Clin Biochem       Date:  2007-11       Impact factor: 2.057

10.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.

Authors:  Angela Dispenzieri; Robert A Kyle; Jerry A Katzmann; Terry M Therneau; Dirk Larson; Joanne Benson; Raynell J Clark; L Joseph Melton; Morie A Gertz; Shaji K Kumar; Rafael Fonseca; Diane F Jelinek; S Vincent Rajkumar
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

View more
  2 in total

1.  Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.

Authors:  Paola Tacchetti; Annalisa Pezzi; Elena Zamagni; Lucia Pantani; Serena Rocchi; Beatrice Anna Zannetti; Katia Mancuso; Ilaria Rizzello; Michele Cavo
Journal:  Haematologica       Date:  2016-12-01       Impact factor: 9.941

2.  Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

Authors:  Thomas Dejoie; Jill Corre; Helene Caillon; Cyrille Hulin; Aurore Perrot; Denis Caillot; Eileen Boyle; Marie-Lorraine Chretien; Jean Fontan; Karim Belhadj; Sabine Brechignac; Olivier Decaux; Laurent Voillat; Philippe Rodon; Olivier Fitoussi; Carla Araujo; Lotfi Benboubker; Charlotte Fontan; Mourad Tiab; Pascal Godmer; Odile Luycx; Olivier Allangba; Jean-Michel Pignon; Jean-Gabriel Fuzibet; Laurence Legros; Anne Marie Stoppa; Mamoun Dib; Brigitte Pegourie; Frederique Orsini-Piocelle; Lionel Karlin; Bertrand Arnulf; Murielle Roussel; Laurent Garderet; Mohamad Mohty; Nathalie Meuleman; Chantal Doyen; Pascal Lenain; Margaret Macro; Xavier Leleu; Thierry Facon; Philippe Moreau; Michel Attal; Herve Avet-Loiseau
Journal:  Blood       Date:  2016-10-11       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.